Skip to main content
Figure 7 | BMC Cancer

Figure 7

From: The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma

Figure 7

ROS production in MES-MM98 cells left untreated (control) or treated with everolimus 10 nM, sorafenib 5 μM and their combination for 24 h and then stained with the ROS-specific MitoSOX™ probe. (A) Confocal microscopy photomicrographs. Nuclei are counterstained with Hoechst 33342 bar = 10 μm. (B) Histograms of flow cytometry analysis.

Back to article page